Scopolamine Treatment for Patients With Organophosphate Poisoning

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala

Ingia / Ingia

Kiungo kimehifadhiwa kwenye clipboard

Hali

Wadhamini

Assaf-Harofeh Medical Center

Washirika

Israeli MOH

International Diabetes Federation

JARIBIO LA KLINIKI: NCT00389259

BioSeek: nct00389259

Maneno muhimu

Kikemikali

Organophosphate (OP) compounds are a major threat as chemical warfare agents or in terrorist act. OPs are also the active ingredient of many insecticides. Ingestion of insecticides is a common cause of death among people who commit suicide in developing countries. OPs poisoning also frequently occurs after accidental exposure to agricultural OPs and in children as a result of unintentional ingestion.

The use of competitive inhibitors of acetylcholine other than atropine for patient with organophosphate (OP) poisoning is controversial. Because scopolamines' ability to cross the blood brain barrier is better than atropine, it has been suggested that scopolamine should be used OP poisoned patients who have central nervous system (CNS) manifestations. However there is controversy regarding its potential benefit in the treatment of organophosphate poisoning in humans. To the best of our knowledge there are no randomised controlled studies on the use of scopolamine in humans. This prospective randomised controlled study is aimed to determine whether adding scopolamine to the standard treatment of atropine and oximes in patients with CNS symptoms of OP poisoning improve the outcome.

Maelezo

Objective: to determine whether adding scopolamine to the standard treatment of atropine and oximes improve the outcome of patients with OP poisoning and CNS manifestations. Design: A multi-center, randomized, double blind, placebo controlled study. Setting: Emergency Departments & Intensive Care Units in Israel. Participants: Patients 2 -60 years old with acute OP poisoning and CNS manifestations. Interventions: In addition to standard treatment with atropine and obidoxime, eligible patients will be randomly assigned to one of two treatment groups, scopolamine group, and placebo group (both given in the same volume). Scopolamine will be given IM or IV in a dose of 0.25mg for adults and 0.006mg/kg for children every 4 hours. At least three doses of scopolamine (or placebo) will be given. The medical staff will be blinded to the treatment given. Main outcome measures: Improvement in neurological status, duration of seizures and number of days on ventilator. Data analysis: The main outcome measures, will be compared using the Student's t-test or the Mann-Whitney tests as appropriate. The *2 or Fisher Exact tests, as appropriate, will be used for comparisons of categorical variables. We will use multiple logistic regression to examine the extent to which variables predict success or failure of the treatment.

Tarehe

Imethibitishwa Mwisho:	02/28/2010
Iliyowasilishwa Kwanza:	10/16/2006
Uandikishaji uliokadiriwa Uliwasilishwa:	10/16/2006
Iliyotumwa Kwanza:	10/17/2006
Sasisho la Mwisho Liliwasilishwa:	04/03/2011
Sasisho la Mwisho Lilichapishwa:	04/04/2011
Tarehe halisi ya kuanza kwa masomo:	09/30/2007
Tarehe ya Kukamilisha Utafiti:	11/30/2009

Hali au ugonjwa

Neurotoxicity Syndromes

Uingiliaji / matibabu

Drug: Placebo

Awamu

Vikundi vya Arm

Mkono	Uingiliaji / matibabu
Experimental: A IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h
Placebo Comparator: B IV Look alike drug Q 4h

Vigezo vya Kustahiki

Zama zinazostahiki Kujifunza	2 Years Kwa 2 Years
Jinsia Inastahiki Kujifunza	All
Hupokea Wajitolea wa Afya	Ndio
Vigezo	Inclusion Criteria: - Age: 2- 60 years - At least two of the following three criteria: - Known exposure to an organophosphate or carbamate insecticide in the last 72 hours. - Symptoms and signs typical to organophosphate poisoning involving at least two systems (gastrointestinal, respiratory, skin, eyes,) See appendix - Low levels of plasma butyrylcholinesterase (less than 50% of the lower normal range ) - CNS involvement in the first 72 hours after exposure: determined by finding at least one of the following major criteria or at least two of the minor criteria Major criteria for CNS involvement: - Seizures - Extrapyramidal or Parkinson like symptoms - Decreased level of consciousness (GCS< 12) Minor criteria for CNS involvement: - GCS 14-12 - Confusion - Hallucinations Exclusion Criteria: - Hypersensitivity to scopolamine - Glaucoma, narrow-angle (angle-closure) - Tachyarrhythmias, congestive heart failure - Obstructive gastrointestinal disease - Myasthenia Gravis - Reflux esophagitis - Ulcerative colitis - Known obstructive uropathy - Pregnancy - Patient or legal guardian unable to give informed consent (see comment under ethics) - Severe co-morbidity (multi-trauma, advanced cancer, etc)

Matokeo

Hatua za Matokeo ya Msingi

1. Improvement in neurological status as measured by the Glasgow Coma Scale [1 week]

2. Duration of seizures. [1 week]

3. Number of days on ventilator [1 week]

Hatua za Matokeo ya Sekondari

1. Total cumulative dose of atropine [1 week]

2. Need for benzodiazepines [1 week]

3. Number of days in the ICU [2 weeks]

4. Adverse effects and complications [2 weeks]

5. Neurological assessment at discharge [2 weeks]

6. Neurological assessment 3 month after the exposure [3 month]

7. Neuro-cognitive assessment at 3 month [3 month]

8. Survival at 24 hours [24 hours]

9. Survival to discharge [4 weeks]

10. Number of days in hospital [4 weeks]